
Evaxion A/S (NASDAQ:EVAX) is redirecting its internal resources toward cancer vaccine development, as the biotechnology company seeks to advance two off-the-shelf candidates and find partners to expand its personalized vaccine beyond melanoma.
Chief Executive Officer Helen Tayton-Martin said on the company’s third-quarter strategy and financial results call that the shift reflects interest in Evaxion’s immuno-oncology capabilities and the potential value of its AI-Immunology platform. The company will continue to seek partners for its infectious disease assets and complete early testing of autoimmune concepts.
Evaxion also reported a $3.5 million net loss for the quarter and said it had extended its cash runway toward the end of 2027, partly through sales under its at-the-market, or ATM, equity program.
Cancer vaccine programs take priority
Evaxion’s oncology plans center on moving EVX-04, an off-the-shelf vaccine candidate for acute myeloid leukemia, and EVX-05, a candidate for glioblastoma, toward clinical development. The latter program is being developed in collaboration with Duke University. The company also plans to use its platform to identify additional cancer antigens and indications.
The company expects to file a clinical trial application for EVX-04 by the end of 2026. Chief Scientific Officer and Chief Operating Officer Birgitte Rønø said the lead candidate was moving into manufacturing and that Evaxion was conducting final preclinical testing and antigen validation. The company plans to present target validation data at the American Society of Hematology meeting in December and may provide more details on the patient population and trial design around the time of the application.
EVX-04 and EVX-05 are designed to target endogenous retroviral antigens identified using the company’s platform. Unlike a personalized vaccine, an off-the-shelf vaccine is designed for a patient population. Tayton-Martin said potential partners have expressed interest in both approaches, while noting that Evaxion’s off-the-shelf approach has not yet been clinically validated.
For EVX-01, the company’s personalized vaccine, Tayton-Martin said Evaxion most likely would seek partners to pursue indications beyond advanced melanoma. She said the existing clinical package and the platform’s ability to identify different types of antigens could support potential studies in other cancers.
Melanoma data and remaining questions
Rønø said the two-year results from Evaxion’s phase 2 EVX-01 study in advanced melanoma showed a 75% objective response rate and a 25% complete response rate. The vaccine was administered with anti-PD-1 therapy, and EVX-01-related adverse events were limited to grades 1 and 2, she said.
In a one-year extension, all six participating patients who received EVX-01 monotherapy maintained their clinical responses through the end of the trial, Rønø said. She added that vaccine-specific T-cell responses were sustained over the three-year period, including after anti-PD-1 treatment ended.
Rønø said the platform achieved 89% precision in predicting immunogenic neoantigens in the study, and that 86% of assessed neoantigen responses were newly induced rather than preexisting. In response to an analyst’s question, however, she said the available data could not fully answer whether CD8+ immune responses correlated with clinical responses because the immune dataset was limited for patients whose disease progressed early.
The process from biopsy to vaccine administration currently takes about seven weeks. Rønø said consolidating work performed by multiple manufacturing partners and reducing shipping could shorten that turnaround.
Cash runway and other programs
Evaxion’s third-quarter net loss compared with a $4.6 million profit a year earlier. Chief Financial Officer Thomas Schmidt said the company recognized no revenue in the latest quarter, while the prior-year period included revenue associated with licensing EVX-B3 to Merck, known as MSD outside the U.S. and Canada.
Cash totaled $13.3 million at the end of September, including $2.2 million raised through the ATM program in August. Evaxion received another $800,000 under the program in October, which was included in its runway estimate but not in the September cash balance. The company maintained its expected annual cash burn of approximately $14 million.
Outside oncology, Tayton-Martin said Evaxion continues to pursue partnerships for its infectious disease candidates. She said EVX-B3 was moving forward with MSD and that EVX-B2 work was continuing with Afrigen.
Evaxion also intends to complete early laboratory testing of two autoimmune concepts: a tolerogenic vaccine and an approach using autoantibody binders. Rønø said the company hopes to attract partner interest before defining a product candidate.
About Evaxion A/S (NASDAQ:EVAX)
Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.
